In accord with ASX requirements, Imagion Biosystems has lodged “Appendix 4C, Quarterly report for entities subject to Listing Rule 4.7B” for the Quarter ended 30 September 2017.
View Appendix 4C for Q3, 2017.
Quarterly Activity Report – Quarter ending 31 December 2023
Highlights: Announced positive results from IBI10103 Phase I Study demonstrating safety and clinical feasibility of molecular MRI with MagSense® HER2 Imaging Agent Presented new animal